AACI Thanks House Committee on Oversight and Government Reform for Supporting Federally Funded Cancer Research

This morning, Mary Beckerle, PhD, Chief Executive Officer and Director of Huntsman Cancer Institute University of Utah, Elizabeth Jaffee, MD, Deputy Director, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Tyler Jacks, PhD, Director, Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, and Mrs. Tammi Carr, the mother of Chad Carr, a child who suffered from Diffuse Intrinsic Pontine Glioma, testified before the Full House Committee on Oversight and Government Reform to discuss federally funded cancer research.

beckerle

Dr. Mary Beckerle testifies on Capitol Hill about the federal government’s irreplaceable role in supporting cancer research.

AACI thanks Chairman Jason Chaffetz (R-UT), Ranking Member Elijah Cummings (D-MD) and members of the Committee for welcoming the witnesses and learning about the importance of federally funded cancer research.

In his opening remarks, Chairman Chaffetz noted his own family’s experience with cancer as his mother succumbed to breast cancer after a ten-year fight.  He said he objected to the president’s proposed budget for Fiscal Year 2018 for the National Institutes of Health (NIH).

Ranking Member Cummings said there are few investments more significant than those made in biomedical research; that the work of the NIH is transformational and has the power to turn ideas into cures.  He noted research generates economic activity in every state across the country and allows the U.S. to grow the science and technology workforce to the benefit of individuals across the world.

During her testimony, Dr. Beckerle noted the federal government has an unmatched and irreplaceable role in supporting cancer research, saying “no other public, corporate, or charitable entity is able to provide the broad and sustained investment in research necessary to enable successes.”

For her part, Dr. Jaffee noted the state of science and medicine are at a crossroads.  She said the cancer community is in the middle of a revolution, turning decades of government investment into real treatments that are saving lives, yet the instability of government funding for research without significant increases in the past decade has created a crisis as young scientists are turning elsewhere for positions outside academia or outside the U.S. altogether. Dr. Jaffee said the U.S. stands to lose the brightest minds.

Dr. Jacks acknowledged the investments in the NIH and NCI have been the foundation of progress against cancer and have allowed the U.S. to enter a new era.  He said the research is an effective use of taxpayer dollars and the bulk of the support in universities and other laboratories comes from the NIH.

Mrs. Carr suggested rather than decreasing the NIH budget, Congress should provide increases in order to help patients like her son, Chad.  Many members of the Committee agreed with Mrs. Carr and expressed their disapproval of the president’s proposed budget for Fiscal Year 2018.

At a time when funding for biomedical research is under threat, AACI expresses its gratitude to Chairman Chaffetz, Ranking Member Cummings, and other members of the Committee for showing their support for federally funded cancer research.  Stable, predictable funds for the NIH and NCI are vital to making progress in cancer prevention and advancing cancer research and treatment to benefit all patients.

AACI continues to urge members of Congress to reject the president’s proposed budget for Fiscal Year 2018 and asks that they complete a spending package for the NIH for Fiscal Year 2017 in the amount approved by the Senate Appropriations Committee last year, bringing the recommended funding level for the NIH in Fiscal Year 2017 to $34.1 billion and to provide at least $2 billion above that for Fiscal Year 2018.

Watch the entire hearing here.

Jennifer W. Pegher, Director, Government Relations

AACI Strongly Opposes President’s Cuts to NIH in Fiscal Year 2018 “Skinny Budget”

The Association of American Cancer Institutes (AACI) expresses opposition to President Donald Trump’s proposed “skinny budget” for Fiscal Year (FY) 2018. The President’s recommendation would cut funding to the National Institutes of Health (NIH) by $6 billion, or approximately 19 percent, which translates to a cut of nearly $1 billion in funding to the National Cancer Institute (NCI). These drastic cuts to the NIH and NCI would significantly reduce each budget to the equivalent of FY 2002 funding levels.white-house

While cancer centers were encouraged by the funding stream included in the 21st Century Cures Act, this fund is not a sufficient alternative to appropriations for the NIH and NCI and would not cover the extreme budget reductions proposed in the “skinny budget.” Additionally, the federal government has yet to fund the NIH and NCI for FY 2017, as it continues to operate at FY 2016 levels.

AACI Executive Director Barbara Duffy Stewart, MPH, said in response to the President’s proposal, “Federal investments in cancer research have led to advancements in our understanding of cancer and groundbreaking research that has the potential to accelerate progress faster than ever before. A severely reduced biomedical research budget would diminish academic cancer centers’ ability to develop and discover breakthrough therapies and treatments for patients, and potentially sideline promising research projects that are still under review for funding.”

AACI institutions house more than 20,000 scientific, clinical and public health investigators who collaborate in order to translate research findings into new approaches to preventing and treating cancer, but there is more to be done to make continued progress. These institutions are beacons of discovery and are largely funded by the NIH and NCI, which rely on stable and predictable federal funding to invest in groundbreaking cancer research.

Stewart added, “AACI cancer centers are at the forefront of developing new methods for the prevention and detection of cancers and the delivery of high quality cancer care. The proposed cuts to the NIH and NCI budget for FY 2018 are unacceptable. We join our colleagues in the biomedical research community in urging members of Congress to reject President Trump’s proposed cuts to NIH and provide a robust federal investment to the NIH and NCI for not only the current Fiscal Year, but for FY 2018 and beyond.”